澳大利亚减肥药物补贴政策引发公平性讨论

澳大利亚正面临一项卫生政策选择：是否应补贴GLP-1类减肥药物。目前约50万澳大利亚人正在使用这类药物，包括Ozempic、Wegovy和Mounjaro等，其中近半数患者私自购买，月费介于200至700澳元之间。1一项涉及近28000人的2025年综述显示，司美格鲁肽可导致平均体重减少约11%。1

这类药物的高成本成为持续治疗的主要障碍，特别是对低收入人群而言。1研究表明，50%以上的用户在6个月内因无法负担费用而停止治疗。1停药后患者在一年内会重新获得约60%的体重，意味着这类药物需要长期持续用药才能维持效果。1

当前的高成本机制加剧了医疗不公平。肥胖症和2型糖尿病在低社会经济地位人群、地区偏远社区和原住民中的发病率更高，1这表明那些最需要治疗的群体往往最难获得相关药物。

Approximately 500,000 Australians are currently using GLP-1 weight loss medications such as Ozempic, Wegovy, and Mounjaro, with nearly half obtaining these drugs through private purchase at a monthly cost ranging from A$200 to A$700 1. A 2025 systematic review involving close to 28,000 participants found that semaglutide resulted in an average weight loss of approximately 11% 1. However, the sustainability of treatment remains a significant challenge, as research indicates that over 50% of users discontinue treatment within six months, primarily due to inability to afford ongoing costs 1. Following cessation of medication, patients typically regain approximately 60% of their lost weight within one year 1.

The question of whether subsidising these medications could advance health equity warrants consideration, particularly given that obesity and type 2 diabetes disproportionately affect populations with lower socioeconomic status, residents of remote communities, and Indigenous Australians 1. The high out-of-pocket expenses constitute a substantial barrier to continued treatment, especially for lower-income groups who bear the greatest burden of weight-related disease 1. Policymakers must weigh the potential benefits of improved access against the long-term costs of maintaining treatment, since the medications require continuous use to sustain their effects 1.